Owlet (OWLT) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Q2 2024 revenue grew 58% year-over-year to $20.7 million, driven by strong Dream Sock sales, expanded market access in Europe after CE Medical certification, and increased consumer demand across all channels.
Gross margin improved to 50% from 40% in Q2 2023, reflecting higher revenue, favorable product mix, and lower direct and fulfillment costs.
Operating loss narrowed to $2.2 million from $6.7 million in Q2 2023; net loss was $1.1 million, improved from $8.5 million, with adjusted EBITDA turning positive at $0.1 million.
Record-breaking Amazon Prime event and strong launches in the UK and Europe supported top-line growth; new subscription service and telehealth partnership launched.
Cash and cash equivalents stood at $15.4 million as of June 30, 2024, with negative cash flows from operations of $6.7 million for the first half of 2024.
Financial highlights
Q2 2024 net revenue was $20.7 million, up 58% year-over-year; gross billings were $26.9 million, up 59%.
Gross margin reached 50%, up over 1,000 basis points from Q2 2023.
Operating loss narrowed to $2.2 million; net loss was $1.1 million; adjusted EBITDA was $0.1 million, a significant improvement from a $4.3 million loss in Q2 2023.
Net loss attributable to common stockholders for Q2 2024: $2.7 million ($0.30/share), compared to $9.8 million ($1.19/share) in Q2 2023.
Cash used in operations for H1 2024: $6.7 million, a reduction from $16.8 million used in H1 2023.
Outlook and guidance
H2 2024 net revenue expected between $37 million and $42 million; gross margins of 46%-50%; adjusted EBITDA loss of $3 million to break even.
Full-year 2024 net revenue guidance is $72.5 million-$77.5 million, gross margins of 47%-49%, and adjusted EBITDA loss of $6 million-$3 million.
Management highlights ongoing risks to liquidity and the need for additional financing to support operations and strategic initiatives.
Anticipates BabySat and subscription product revenue to ramp in 2024 and drive impact in 2025.
Latest events from Owlet
- Up to 9.6 million shares registered for resale by major holders; no proceeds to the company.OWLT
Registration Filing10 Mar 2026 - Record revenue, margin, and subscriber growth; strong 2026 outlook with global and AI expansion.OWLT
Q4 20255 Mar 2026 - Q1 revenue up 43% with record margin, breakeven EBITDA, and raised guidance amid ongoing risks.OWLT
Q1 20253 Feb 2026 - Dual FDA clearances and strong retail momentum position the company for rapid growth and margin expansion.OWLT
TD Cowen’s 8th Annual Future of the Consumer Conference1 Feb 2026 - Q3 revenue up 141% to $22.1M, record margin, positive EBITDA, but liquidity risks remain.OWLT
Q3 202414 Jan 2026 - Record 2024 results, new FDA-cleared products, and margin gains set up for 2025 profitability.OWLT
Q4 202426 Dec 2025 - Proposes up to $100M in securities offerings to fund digital infant health solutions amid key risks.OWLT
Registration Filing16 Dec 2025 - Resale registration for 750,000 shares tied to a term loan, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025 - Registration enables major investors to resell 5.3M shares, with no proceeds to the company.OWLT
Registration Filing16 Dec 2025